Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Field Study to Evaluate the Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario

NCT02177721 is registered in ClinicalTrials.gov with Emergent BioSolutions as lead sponsor.

NCT NCT02177721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02177721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Field Study to Evaluate the Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario
Lead sponsor
Emergent BioSolutions
Phase
Phase 4
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
December 31, 2035
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

infections, bacterial